Xrcc1 (X-ray repair cross complementing 1) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Xrcc1 (X-ray repair cross complementing 1) Rattus norvegicus
Symbol: Xrcc1
Name: X-ray repair cross complementing 1
RGD ID: 619823
Description: Predicted to enable several functions, including ADP-D-ribose modification-dependent protein binding activity; oxidized DNA binding activity; and poly-ADP-D-ribose binding activity. Predicted to contribute to 3' overhang single-stranded DNA endodeoxyribonuclease activity. Involved in several processes, including base-excision repair; response to hypoxia; and response to xenobiotic stimulus. Predicted to be located in chromosome, telomeric region; nucleolus; and nucleoplasm. Predicted to be part of ERCC4-ERCC1 complex and chromatin. Predicted to be active in nucleus and site of DNA damage. Used to study in situ carcinoma. Biomarker of asphyxia neonatorum; transient cerebral ischemia; and visual epilepsy. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); carcinoma (multiple); central nervous system cancer (multiple); gastrointestinal system cancer (multiple); and hematologic cancer (multiple). Orthologous to human XRCC1 (X-ray repair cross complementing 1); PARTICIPATES IN base excision repair pathway; nucleotide excision repair pathway; INTERACTS WITH (+)-pilocarpine; (+)-schisandrin B; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
Previously known as: DNA repair protein XRCC1; X-ray repair complementing defective repair in Chinese hamster cells 1; x-ray repair cross-complementing group 1 protein; X-ray repair cross-complementing protein 1
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2180,140,495 - 80,168,705 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl180,141,207 - 80,168,701 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx185,534,876 - 85,562,653 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0194,084,721 - 94,112,152 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0187,290,702 - 87,318,402 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0181,412,635 - 81,441,680 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl181,413,353 - 81,441,678 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0182,673,571 - 82,701,082 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4179,834,167 - 79,860,300 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1179,912,277 - 79,938,411 (+)NCBI
Celera174,594,313 - 74,621,523 (+)NCBICelera
Cytogenetic Map1q21NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
5 Alpha Fluorouracil Toxicity  (ISO)
acute lymphoblastic leukemia  (ISO)
asphyxia neonatorum  (IEP)
autosomal recessive spinocerebellar ataxia 26  (ISO)
B-Cell Chronic Lymphocytic Leukemia  (ISO)
Birth Weight  (ISO)
brain glioma  (ISO)
Breast Neoplasms  (ISO)
cataract  (ISO)
central nervous system cancer  (ISO)
cervical cancer  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
Chronic Hepatitis C  (ISO)
chronic myeloid leukemia  (ISO)
colorectal adenocarcinoma  (ISO)
colorectal cancer  (ISO)
colorectal carcinoma  (ISO)
contact dermatitis  (ISO)
coronary artery disease  (ISO)
diabetic retinopathy  (ISO)
Erythema  (ISO)
esophageal cancer  (ISO)
esophagus squamous cell carcinoma  (ISO)
ethylmalonic encephalopathy  (ISO)
gallbladder cancer  (ISO)
gastric cardia adenocarcinoma  (ISO)
gastric cardia carcinoma  (ISO)
genetic disease  (ISO)
glioblastoma  (ISO)
hepatitis A  (ISO)
hepatitis B  (ISO)
hepatocellular carcinoma  (ISO)
high grade glioma  (ISO)
Human Viral Hepatitis  (ISO)
hypertension  (ISO)
impotence  (ISO)
in situ carcinoma  (IDA)
invasive ductal carcinoma  (ISO)
laryngeal carcinoma  (ISO)
laryngeal squamous cell carcinoma  (ISO)
leiomyoma  (ISO)
liver cancer  (ISO)
liver cirrhosis  (ISO)
lung adenocarcinoma  (ISO)
lung cancer  (ISO)
lung non-small cell carcinoma  (ISO)
male infertility  (ISO)
malignant mesothelioma  (ISO)
meningioma  (ISO)
Mesothelioma  (ISO)
Micronuclei, Chromosome-Defective  (ISO)
Mouth Neoplasms  (ISO)
myelodysplastic syndrome  (ISO)
nasopharynx carcinoma  (ISO)
Neoplasm Metastasis  (ISO)
Occupational Diseases  (ISO)
oral mucosa leukoplakia  (ISO)
pancreatic cancer  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
renal cell carcinoma  (ISO)
Reperfusion Injury  (IEP)
Salivary Gland Neoplasms  (ISO)
schizophrenia  (ISO)
seminoma  (ISO)
senile cataract  (ISO)
stomach cancer  (ISO)
stomach carcinoma  (ISO)
Stomach Neoplasms  (ISO)
stomatitis  (ISO)
thyroid gland papillary carcinoma  (ISO)
transient cerebral ischemia  (IEP)
transitional cell carcinoma  (ISO)
type 2 diabetes mellitus  (ISO)
urinary bladder cancer  (ISO)
visual epilepsy  (IEP)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-dexrazoxane  (ISO)
(+)-pilocarpine  (EXP)
(+)-schisandrin B  (EXP)
(-)-epigallocatechin 3-gallate  (ISO)
(-)-quinic acid  (ISO)
(S)-nicotine  (ISO)
1,2-dimethylhydrazine  (ISO)
1-methylphenanthrene  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-tribromophenol  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4,4'-sulfonyldiphenol  (EXP)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
4-hydroperoxycyclophosphamide  (EXP)
4-hydroxyphenyl retinamide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-fluorouracil  (ISO)
5-formyltetrahydrofolic acid  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
7,9-dihydro-1H-purine-2,6,8(3H)-trione  (ISO)
acrylamide  (ISO)
all-trans-retinoic acid  (ISO)
ammonium chloride  (EXP)
amphibole asbestos  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
asbestos  (ISO)
belinostat  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
Benzo[ghi]perylene  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (EXP)
bleomycin A2  (ISO)
buta-1,3-diene  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
caffeine  (ISO)
camptothecin  (ISO)
carbamazepine  (ISO)
chloroethene  (EXP,ISO)
chlorpyrifos  (ISO)
chromium(6+)  (ISO)
cisplatin  (ISO)
clofibrate  (ISO)
copper(II) sulfate  (ISO)
coumarin  (ISO)
crocidolite asbestos  (ISO)
curcumin  (ISO)
cyclophosphamide  (EXP)
cyproconazole  (EXP)
cytarabine  (ISO)
decabromodiphenyl ether  (ISO)
deoxynivalenol  (ISO)
dexamethasone  (ISO)
doxorubicin  (ISO)
emodin  (EXP)
epoxiconazole  (EXP)
ethanol  (ISO)
ethyl methanesulfonate  (ISO)
etoposide  (ISO)
fipronil  (EXP)
flavonoids  (ISO)
floxuridine  (ISO)
fluoranthene  (ISO)
folic acid  (ISO)
formaldehyde  (ISO)
furan  (EXP,ISO)
gefitinib  (ISO)
genistein  (ISO)
ginsenoside Rg1  (ISO)
glutathione  (ISO)
hydrogen peroxide  (ISO)
idarubicin  (ISO)
indometacin  (ISO)
ivermectin  (ISO)
L-ascorbic acid  (ISO)
lead chromate  (ISO)
lead(0)  (ISO)
levetiracetam  (EXP)
lipopolysaccharide  (ISO)
lupeol  (ISO)
LY294002  (ISO)
malonaldehyde  (ISO)
mancozeb  (ISO)
metformin  (ISO)
methamphetamine  (ISO)
methyl methanesulfonate  (ISO)
mithramycin  (ISO)
Monobutylphthalate  (EXP)
N-acetyl-L-cysteine  (ISO)
N-ethyl-N-nitrosourea  (ISO)
N-methyl-4-phenylpyridinium  (ISO)
NAD zwitterion  (ISO)
NAD(+)  (ISO)
nicotine  (ISO)
olaparib  (ISO)
oxaliplatin  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
pioglitazone  (ISO)
piperonyl butoxide  (ISO)
platinum  (ISO)
platinum(0)  (ISO)
reactive oxygen species  (ISO)
resveratrol  (EXP,ISO)
S-adenosyl-L-methioninate  (ISO)
S-adenosyl-L-methionine  (ISO)
SB 431542  (ISO)
sodium arsenite  (ISO)
styrene  (ISO)
styrene oxide  (ISO)
sunitinib  (ISO)
tamoxifen  (ISO)
temozolomide  (ISO)
tetrachloromethane  (EXP)
theaflavin  (ISO)
thioacetamide  (EXP)
trichloroethene  (EXP)
triptonide  (ISO)
troglitazone  (ISO)
tunicamycin  (ISO)
ubiquinones  (ISO)
usnic acid  (ISO)
valproic acid  (ISO)
veliparib  (ISO)
vorinostat  (ISO)

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. Akulevich NM, etal., Endocr Relat Cancer. 2009 Jun;16(2):491-503. doi: 10.1677/ERC-08-0336. Epub 2009 Mar 13.
2. Genetic polymorphisms and metastatic breast cancer survival. Allen-Brady K Future Oncol. 2007 Apr;3(2):155-8.
3. The X-ray repair cross complementing protein 1 (XRCC1) rs25487 polymorphism and susceptibility to cirrhosis in Brazilian patients with chronic viral hepatitis. Almeida Pereira Leite ST, etal., Ann Hepatol. 2013 Sep-Oct;12(5):733-9.
4. DNA repair gene hOGG1 codon 326 and XRCC1 codon 399 polymorphisms and bladder cancer risk in a Japanese population. Arizono K, etal., Jpn J Clin Oncol. 2008 Mar;38(3):186-91. doi: 10.1093/jjco/hym176. Epub 2008 Feb 12.
5. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. Artac M, etal., J Cancer Res Clin Oncol. 2010 Jun;136(6):803-9. doi: 10.1007/s00432-009-0720-3. Epub 2009 Nov 12.
6. DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. Batar B, etal., Leuk Res. 2009 Jun;33(6):759-63. doi: 10.1016/j.leukres.2008.11.005. Epub 2008 Dec 19.
7. The X-ray Repair Cross-Complementing Group 1 Arg399Gln Genetic Polymorphism and Risk of Hepatocellular Carcinoma in an Iranian Population. Bazgir A, etal., Middle East J Dig Dis. 2018 Jan;10(1):40-44. doi: 10.15171/mejdd.2017.89. Epub 2018 Jan 10.
8. The genetic association database. Becker KG, etal., Nat Genet. 2004 May;36(5):431-2.
9. Association study of single nucleotide polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in Chinese Han population. Bi J, etal., Biomed Res Int. 2013;2013:138785. doi: 10.1155/2013/138785. Epub 2013 Jul 30.
10. Genetic polymorphisms of CYP2E1 and DNA repair genes HOGG1 and XRCC1: association with hepatitis B related advanced liver disease and cancer. Bose S, etal., Gene. 2013 May 1;519(2):231-7. doi: 10.1016/j.gene.2013.02.025. Epub 2013 Feb 27.
11. An intronic polymorphism associated with increased XRCC1 expression, reduced apoptosis and familial breast cancer. Bu D, etal., Breast Cancer Res Treat. 2006 Oct;99(3):257-65. Epub 2006 Apr 5.
12. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Burri RJ, etal., Radiat Res. 2008 Jul;170(1):49-59.
13. Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. Cao Y, etal., BMC Cancer. 2006 Jun 26;6:167. doi: 10.1186/1471-2407-6-167.
14. Investigating the association between XRCC1 gene polymorphisms and susceptibility to gastric cancer. Chen S, etal., Genet Mol Res. 2016 Sep 9;15(3). pii: gmr8342. doi: 10.4238/gmr.15038342.
15. Haplotype analysis of the XRCC1 gene and laryngeal cancer. Chen W, etal., Genet Test Mol Biomarkers. 2014 Jul;18(7):525-9. doi: 10.1089/gtmb.2013.0434. Epub 2014 Jun 23.
16. Interplay between base excision repair protein XRCC1 and ALDH2 predicts overall survival in lung and liver cancer patients. Chen X, etal., Cell Oncol (Dordr). 2018 Oct;41(5):527-539. doi: 10.1007/s13402-018-0390-8. Epub 2018 Aug 7.
17. Association between the c.910A>G genetic variant of the XRCC1 gene and susceptibility to esophageal cancer in the Chinese Han population. Chen XQ, etal., Braz J Med Biol Res. 2013 Dec;46(12):1028-1032. doi: 10.1590/1414-431X20133396. Epub 2013 Dec 2.
18. mRNA levels of the hypoxia inducible factor (HIF-1) and DNA repair genes in perinatal asphyxia of the rat. Chiappe-Gutierrez M, etal., Life Sci. 1998;63(13):1157-67.
19. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. De Ruyck K, etal., Mutat Res. 2007 Jul 28;631(2):101-10. doi: 10.1016/j.mrgentox.2007.03.010. Epub 2007 Apr 21.
20. Association between the C.1161G>A and C.1779C>G genetic variants of XRCC1 gene and hepatocellular carcinoma risk in Chinese population. Deng X, etal., Int J Biol Sci. 2013;9(3):289-94. doi: 10.7150/ijbs.5928. Epub 2013 Mar 7.
21. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Divine KK, etal., Mutat Res. 2001 Jan 5;461(4):273-8. doi: 10.1016/s0921-8777(00)00059-8.
22. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population. Du Y, etal., Clin Respir J. 2016 May;10(3):311-7. doi: 10.1111/crj.12218. Epub 2014 Nov 3.
23. The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer. Dufloth RM, etal., Genet Mol Res. 2008 Jul 1;7(3):574-82.
24. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy. Erčulj N, etal., J Thorac Oncol. 2012 Oct;7(10):1609-17. doi: 10.1097/JTO.0b013e3182653d31.
25. DNA base excision repair and nucleotide excision repair proteins in malignant salivary gland tumors. Felix FA, etal., Arch Oral Biol. 2021 Jan;121:104987. doi: 10.1016/j.archoralbio.2020.104987. Epub 2020 Nov 11.
26. XRCC1 Gene Polymorphisms and miR-21 Expression in Patients with Colorectal Carcinoma. Fouad H, etal., Eurasian J Med. 2017 Jun;49(2):132-136. doi: 10.5152/eurasianjmed.2017.17021.
27. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Ganster C, etal., Genes Chromosomes Cancer. 2009 Sep;48(9):760-7. doi: 10.1002/gcc.20680.
28. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
29. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
30. Evaluation of candidate genes associated with hepatitis A and E virus infection in Chinese Han population. Gu M, etal., Virol J. 2018 Mar 20;15(1):47. doi: 10.1186/s12985-018-0962-2.
31. XRCC1 and XPD polymorphisms and their relation to the clinical course in hepatocarcinoma patients. Guan Q, etal., Oncol Lett. 2017 Sep;14(3):2783-2788. doi: 10.3892/ol.2017.6522. Epub 2017 Jul 5.
32. Variant Alleles in XRCC1 Arg194Trp and Arg399Gln Polymorphisms Increase Risk of Gastrointestinal Cancer in Sabah, North Borneo. Halim NH, etal., Asian Pac J Cancer Prev. 2016;17(4):1925-31. doi: 10.7314/apjcp.2016.17.4.1925.
33. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Hao B, etal., Oncogene. 2006 Jun 15;25(25):3613-20. doi: 10.1038/sj.onc.1209355. Epub 2006 May 1.
34. Paternal exposure to cyclophosphamide induces DNA damage and alters the expression of DNA repair genes in the rat preimplantation embryo. Harrouk W, etal., Mutat Res 2000 Nov 9;461(3):229-41.
35. Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Hirata H, etal., Biochem Biophys Res Commun. 2006 Apr 21;342(4):1058-62. Epub 2006 Feb 17.
36. [Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism]. Hong CY, etal., Ai Zheng. 2009 Dec;28(12):1291-7. doi: 10.5732/cjc.009.10139.
37. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Hong YC, etal., Int J Cancer. 2005 Sep 1;116(3):428-32. doi: 10.1002/ijc.21019.
38. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Hsu LI, etal., Toxicol Appl Pharmacol. 2008 Apr 15;228(2):144-55. Epub 2007 Dec 14.
39. Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Huang X, etal., Oncol Lett. 2017 Feb;13(2):704-714. doi: 10.3892/ol.2016.5496. Epub 2016 Dec 14.
40. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Hung RJ, etal., Am J Epidemiol. 2005 Nov 15;162(10):925-42. Epub 2005 Oct 12.
41. DNA repair gene XRCC1 Arg399Gln polymorphism is associated with increased risk of uterine leiomyoma. Jeon YT, etal., Hum Reprod. 2005 Jun;20(6):1586-9. Epub 2005 Mar 10.
42. Do genetic defects of DNA repair relevant proteins alter susceptibility to hypertension? A case-control study in northeastern Han Chinese. Jia N, etal., Clin Chim Acta. 2015 Feb 20;441:171-5. doi: 10.1016/j.cca.2014.12.017. Epub 2014 Dec 18.
43. Genetic polymorphisms of XRCC1 gene and susceptibility to hepatocellular carcinoma in Chinese population. Jiang T, etal., Med Oncol. 2014 Apr;31(4):887. doi: 10.1007/s12032-014-0887-6. Epub 2014 Feb 26.
44. Analyzing the association between XRCC1 c.1804C>A genetic variant and lung cancer susceptibility in the Chinese population. Jin JJ, etal., Genet Mol Res. 2016 Jun 10;15(2). pii: gmr4661. doi: 10.4238/gmr.15024661.
45. Association of XPD (Lys751Gln) and XRCC1 (Arg280His) gene polymorphisms in myelodysplastic syndrome. Joshi D, etal., Ann Hematol. 2016 Jan;95(1):79-85.
46. Assoication of XRCC1 gene polymorphisms with risk of non-small cell lung cancer. Kang S, etal., Int J Clin Exp Pathol. 2015 Apr 1;8(4):4171-6. eCollection 2015.
47. DNA repair genes polymorphisms and risk of colorectal cancer in Saudi patients. Karam RA, etal., Arab J Gastroenterol. 2016 Sep;17(3):117-120. doi: 10.1016/j.ajg.2016.08.005. Epub 2016 Sep 27.
48. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Kim K, etal., Gynecol Oncol. 2008 Dec;111(3):509-15. Epub 2008 Oct 12.
49. Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population. Kiran M, etal., Mol Cell Biochem. 2009 Jul;327(1-2):7-13. doi: 10.1007/s11010-009-0035-3. Epub 2009 Feb 5.
50. XRCC1 and XRCC3 variants and risk of glioma and meningioma. Kiuru A, etal., J Neurooncol. 2008 Jun;88(2):135-42. doi: 10.1007/s11060-008-9556-y.
51. Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways. Korashy HM, etal., Anticancer Res. 2017 Sep;37(9):4899-4909. doi: 10.21873/anticanres.11899.
52. A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Lao T, etal., Mutagenesis. 2008 Nov;23(6):523-32. Epub 2008 Sep 2.
53. Genetic polymorphisms of XRCC1 and risk of the esophageal cancer. Lee JM, etal., Int J Cancer. 2001 Jul 20;95(4):240-6. doi: 10.1002/1097-0215(20010720)95:4<240::aid-ijc1041>3.0.co;2-1.
54. DNA polymerases and repair synthesis in NER in human cells. Lehmann AR DNA Repair (Amst). 2011 Jul 15;10(7):730-3. doi: 10.1016/j.dnarep.2011.04.023. Epub 2011 May 20.
55. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. Li D, etal., J Clin Oncol. 2006 Apr 10;24(11):1720-8. Epub 2006 Mar 6.
56. XRCC1 codon 399Gln polymorphism is associated with radiotherapy-induced acute dermatitis and mucositis in nasopharyngeal carcinoma patients. Li H, etal., Radiat Oncol. 2013 Feb 1;8:31. doi: 10.1186/1748-717X-8-31.
57. Ischemic preconditioning induces XRCC1, DNA polymerase-beta, and DNA ligase III and correlates with enhanced base excision repair. Li N, etal., DNA Repair (Amst). 2007 Sep 1;6(9):1297-306. Epub 2007 Apr 6.
58. Association of DNA base-excision repair XRCC1, OGG1 and APE1 gene polymorphisms with nasopharyngeal carcinoma susceptibility in a Chinese population. Li Q, etal., Asian Pac J Cancer Prev. 2013;14(9):5145-51. doi: 10.7314/apjcp.2013.14.9.5145.
59. Evaluation of DNA repair gene XRCC1 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Li QW, etal., Asian Pac J Cancer Prev. 2012;13(1):191-4. doi: 10.7314/apjcp.2012.13.1.191.
60. [The influence of XRCC1 gene polymorphism on the prognosis and safety of stage Ⅲ patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy]. Li RX, etal., Zhonghua Yi Xue Za Zhi. 2021 Mar 23;101(11):759-765. doi: 10.3760/cma.j.cn112137-20200708-02061.
61. Association between a single nucleotide polymorphism of the XRCC1 gene and hepatocellular carcinoma susceptibility in the Chinese Han population. Li XF, etal., Genet Mol Res. 2014 Jan 10;13(1):160-6. doi: 10.4238/2014.January.10.7.
62. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Liu B, etal., Eur J Hum Genet. 2007 Oct;15(10):1049-53. doi: 10.1038/sj.ejhg.5201884. Epub 2007 Jun 27.
63. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer. Liu D, etal., Genet Mol Res. 2014 Apr 17;13(2):3100-7. doi: 10.4238/2014.April.17.6.
64. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcomes of patients with advanced non-small cell lung cancer. Liu JY, etal., Genet Mol Res. 2015 Aug 28;14(3):10331-7. doi: 10.4238/2015.August.28.19.
65. Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis. Liu WB, etal., Biochem Biophys Res Commun. 2011 May 20;408(4):595-601. doi: 10.1016/j.bbrc.2011.04.067. Epub 2011 Apr 21.
66. Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population. Liu Y, etal., Hepatogastroenterology. 2012 Jun;59(116):977-80. doi: 10.5754/hge12187.
67. Association analysis between the c.1804C>A genetic polymorphism of XRCC1 gene and risk of hepatocellular carcinoma in Chinese population. Liu Y, etal., Med Oncol. 2014 Mar;31(3):854. doi: 10.1007/s12032-014-0854-2. Epub 2014 Feb 14.
68. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy. Liu YP, etal., Mol Med Rep. 2013 Jun;7(6):1904-11. doi: 10.3892/mmr.2013.1435. Epub 2013 Apr 22.
69. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Luo KQ, etal., Asian Pac J Cancer Prev. 2013;14(1):449-52. doi: 10.7314/apjcp.2013.14.1.449.
70. Polymorphisms of the DNA repair genes XPD and XRCC1 and the risk of age-related cataract development in Han Chinese. Luo YF, etal., Curr Eye Res. 2011 Jul;36(7):632-6. doi: 10.3109/02713683.2011.571358. Epub 2011 May 20.
71. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. Lv H, etal., Pathol Oncol Res. 2012 Oct;18(4):1009-14. doi: 10.1007/s12253-012-9536-6. Epub 2012 May 2.
72. Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Majumder M, etal., Int J Cancer. 2007 May 15;120(10):2148-56.
73. Polymorphisms of base-excision repair genes and the hepatocarcinogenesis. Mattar MM, etal., Gene. 2018 Oct 30;675:62-68. doi: 10.1016/j.gene.2018.06.056. Epub 2018 Jun 20.
74. XRCC1 haploinsufficiency in mice has little effect on aging, but adversely modifies exposure-dependent susceptibility. McNeill DR, etal., Nucleic Acids Res. 2011 Oct;39(18):7992-8004. doi: 10.1093/nar/gkr280. Epub 2011 Jul 6.
75. Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Miao X, etal., Gastroenterology. 2006 Aug;131(2):420-7. doi: 10.1053/j.gastro.2006.05.050.
76. XRCC1 Gene Polymorphism Increases the Risk of Hepatocellular Carcinoma in Egyptian Population. Naguib M, etal., Asian Pac J Cancer Prev. 2020 Apr 1;21(4):1031-1037. doi: 10.31557/APJCP.2020.21.4.1031.
77. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
78. Polymorphism of the DNA Repair Gene XRCC1 (Arg194Trp) and its role in Colorectal Cancer in Kashmiri Population: a Case Control Study. Nissar S, etal., Asian Pac J Cancer Prev. 2015;16(15):6385-90.
79. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
80. XRCC1 gene polymorphism, diet and risk of colorectal cancer in Thailand. Poomphakwaen K, etal., Asian Pac J Cancer Prev. 2014;15(17):7479-86. doi: 10.7314/apjcp.2014.15.17.7479.
81. Association study of single nucleotide polymorphisms in XRCC1 gene with the risk of gastric cancer in Chinese population. Qiao W, etal., Int J Biol Sci. 2013 Aug 9;9(7):753-8. doi: 10.7150/ijbs.6783. eCollection 2013.
82. Induction of DNA repair proteins, Ref-1 and XRCC1, in adult rat brain following kainic acid-induced seizures. Quach N, etal., Brain Res. 2005 May 3;1042(2):236-40.
83. GOA pipeline RGD automated data pipeline
84. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
85. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
86. Comprehensive gene review and curation RGD comprehensive gene curation
87. DNA repair gene XRCC1 polymorphisms and bladder cancer risk. Sak SC, etal., BMC Genet. 2007 Apr 10;8:13.
88. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Salimizand H, etal., Tumour Biol. 2016 Jan;37(1):791-8. doi: 10.1007/s13277-015-3874-4. Epub 2015 Aug 7.
89. XRCC1 Arg399Gln gene polymorphism and hepatocellular carcinoma risk in the Italian population. Santonocito C, etal., Int J Biol Markers. 2017 May 4;32(2):e190-e194. doi: 10.5301/jbm.5000241.
90. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Shim HJ, etal., Cancer Sci. 2010 May;101(5):1247-54. doi: 10.1111/j.1349-7006.2010.01514.x. Epub 2010 Mar 12.
91. Polymorphisms of XRCC1 and XRCC2 DNA Repair genes and Interaction with Environmental Factors Influence the Risk of Nasopharyngeal Carcinoma in Northeast India. Singh SA and Ghosh SK, Asian Pac J Cancer Prev. 2016;17(6):2811-9.
92. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. Sreeja L, etal., J Cancer Res Clin Oncol. 2008 Jun;134(6):645-52. doi: 10.1007/s00432-007-0328-4. Epub 2007 Oct 19.
93. Single-nucleotide polymorphisms of DNA repair genes OGG1 and XRCC1: association with gallbladder cancer in North Indian population. Srivastava A, etal., Ann Surg Oncol. 2009 Jun;16(6):1695-703. Epub 2009 Mar 6.
94. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Strausberg RL, etal., Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.
95. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Suh KW, etal., Ann Surg Oncol. 2006 Nov;13(11):1379-85. doi: 10.1245/s10434-006-9112-y. Epub 2006 Sep 29.
96. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Sun X, etal., Lung Cancer. 2009 Aug;65(2):230-6. doi: 10.1016/j.lungcan.2008.11.014. Epub 2009 Jan 20.
97. Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) Polymorphisms in Familial and Sporadic Breast Cancer Predisposition and Survival: An Indian Report. Syamala VS, etal., Pathol Oncol Res. 2008 Dec 4.
98. Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients. Tahara T, etal., Anticancer Res. 2011 Feb;31(2):705-10.
99. No association between XRCC1 and XRCC3 gene polymorphisms and breast cancer risk: Iowa Women's Health Study. Thyagarajan B, etal., Cancer Detect Prev. 2006;30(4):313-21. Epub 2006 Sep 11.
100. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Tiseo M, etal., Br J Cancer. 2013 Apr 30;108(8):1695-703. doi: 10.1038/bjc.2013.127. Epub 2013 Apr 2.
101. Association of XRCC1 gene polymorphisms with the susceptibility and chromosomal aberration of testicular germ cell tumors. Tsuchiya N, etal., Int J Oncol. 2006 May;28(5):1217-23.
102. Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia. Tumer TB, etal., Arch Toxicol. 2012 Mar;86(3):431-9. doi: 10.1007/s00204-011-0760-8. Epub 2011 Oct 9.
103. XRCC-1 Gene Polymorphism (Arg399Gln) and Susceptibility to Development of Lung Cancer in Cohort of North Indian Population: A Pilot Study. Uppal V, etal., J Clin Diagn Res. 2014 Nov;8(11):CC17-20. doi: 10.7860/JCDR/2014/10061.5132. Epub 2014 Nov 20.
104. Expression of base excision, mismatch, and recombination repair genes in the organogenesis-stage rat conceptus and effects of exposure to a genotoxic teratogen, 4-hydroperoxycyclophosphamide. Vinson RK and Hales BF, Teratology. 2001 Dec;64(6):283-91.
105. Polymorphism of DNA repair gene xrcc1 and lung cancer risk. Wang H and Liu Z, Cell Biochem Biophys. 2014 Dec;70(3):1881-6. doi: 10.1007/s12013-014-0146-7.
106. The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma. Wang J, etal., Oncotarget. 2017 Aug 10;8(45):78633-78641. doi: 10.18632/oncotarget.20203. eCollection 2017 Oct 3.
107. Association of the XRCC1 c.1178G>A genetic polymorphism with lung cancer risk in Chinese. Wang L, etal., Asian Pac J Cancer Prev. 2014;15(9):4095-9.
108. Roles of XRCC1/XPD/ERCC1 Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization. Wang XC, etal., Genet Test Mol Biomarkers. 2016 Apr;20(4):176-84. doi: 10.1089/gtmb.2015.0267. Epub 2016 Feb 26.
109. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer]. Wang ZH, etal., Ai Zheng. 2004 Aug;23(8):865-8.
110. Radiation cataracts: mechanisms involved in their long delayed occurrence but then rapid progression. Wolf N, etal., Mol Vis. 2008 Feb 5;14:274-85.
111. Association between XRCC1 polymorphisms and laryngeal cancer susceptibility in a Chinese sample population. Wu WQ, etal., Genet Mol Res. 2016 Oct 5;15(4). pii: gmr8525. doi: 10.4238/gmr.15048525.
112. Association study of c.910A>G and c.1686C>G polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in the Chinese population. Xia WF, etal., Genet Mol Res. 2014 Feb 28;13(1):1314-22. doi: 10.4238/2014.February.28.3.
113. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer]. Xu C, etal., Zhongguo Fei Ai Za Zhi. 2011 Dec;14(12):912-7. doi: 10.3779/j.issn.1009-3419.2011.12.03.
114. Zhonghua nan ke xue = National journal of andrology Xu Z, etal., Zhonghua Nan Ke Xue. 2007 Apr;13(4):327-31.
115. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. Yang Y, etal., J Neurochem. 2010 Jan;112(1):134-49. Epub 2009 Oct 15.
116. Genetic polymorphisms of the DNA repair gene and risk of nasopharyngeal carcinoma. Yang ZH, etal., DNA Cell Biol. 2007 Jul;26(7):491-6. doi: 10.1089/dna.2006.0537.
117. Role of DNA repair genes XRCC3 and XRCC1 in predisposition to type 2 diabetes mellitus and diabetic nephropathy. Yesil-Devecioglu T, etal., Endocrinol Diabetes Nutr (Engl Ed). 2019 Feb;66(2):90-98. doi: 10.1016/j.endinu.2018.08.010. Epub 2018 Nov 22.
118. Association of DNA repair gene XRCC1 and lung cancer susceptibility among nonsmoking Chinese women. Yin J, etal., Cancer Genet Cytogenet. 2009 Jan 1;188(1):26-31. doi: 10.1016/j.cancergencyto.2008.08.013.
119. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. Yin Z, etal., BMC Cancer. 2009 Dec 15;9:439. doi: 10.1186/1471-2407-9-439.
120. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. Yu MW, etal., J Natl Cancer Inst. 2003 Oct 1;95(19):1485-8. doi: 10.1093/jnci/djg051.
121. Synergistic association of DNA repair relevant gene polymorphisms with the risk of coronary artery disease in northeastern Han Chinese. Yu X, etal., Thromb Res. 2014 Feb;133(2):229-34. doi: 10.1016/j.thromres.2013.11.017. Epub 2013 Nov 25.
122. Association of DNA repair gene XRCC1 and XPD polymorphisms with genetic susceptibility to gastric cancer in a Chinese population. Yuan T, etal., Cancer Epidemiol. 2011 Apr;35(2):170-4. doi: 10.1016/j.canep.2010.08.008. Epub 2010 Sep 21.
123. Implication of polymorphisms in DNA repair genes in prognosis of hepatocellular carcinoma. Yue AM, etal., Asian Pac J Cancer Prev. 2013;14(1):355-8. doi: 10.7314/apjcp.2013.14.1.355.
124. Association of polymorphisms in X-ray repair cross complementing 1 gene and risk of esophageal squamous cell carcinoma in a Chinese population. Yun YX, etal., Biomed Res Int. 2015;2015:509215. doi: 10.1155/2015/509215. Epub 2015 Feb 1.
125. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Zhang L, etal., Genet Mol Res. 2014 Jan 14;13(1):228-36. doi: 10.4238/2014.January.14.2.
126. Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in Mexican Americans. Zhang L, etal., Hepatology. 2012 Apr;55(4):1008-18. doi: 10.1002/hep.25513.
127. Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy. Zhang L, etal., Int J Clin Exp Med. 2015 Oct 15;8(10):18375-82. eCollection 2015.
128. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Zhang X, etal., Cancer Res. 2005 Feb 1;65(3):722-6.
129. The association between four SNPs of X-ray repair cross complementing protein 1 and the sensitivity to radiotherapy in patients with esophageal squamous cell carcinoma. Zhang Y, etal., Oncol Lett. 2016 May;11(5):3508-3514. doi: 10.3892/ol.2016.4384. Epub 2016 Mar 29.
130. Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Zhao Y, etal., Asian Pac J Cancer Prev. 2012;13(2):665-9. doi: 10.7314/apjcp.2012.13.2.665.
131. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases Zhu SM, etal., Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2004 Jun;22(3):173-5.
Additional References at PubMed
PMID:8532526   PMID:14690602   PMID:15489334   PMID:19633665   PMID:28002403  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2180,140,495 - 80,168,705 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl180,141,207 - 80,168,701 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx185,534,876 - 85,562,653 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0194,084,721 - 94,112,152 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0187,290,702 - 87,318,402 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0181,412,635 - 81,441,680 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl181,413,353 - 81,441,678 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0182,673,571 - 82,701,082 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4179,834,167 - 79,860,300 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1179,912,277 - 79,938,411 (+)NCBI
Celera174,594,313 - 74,621,523 (+)NCBICelera
Cytogenetic Map1q21NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381943,543,311 - 43,575,527 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1943,543,311 - 43,580,473 (-)EnsemblGRCh38hg38GRCh38
GRCh371944,047,463 - 44,079,679 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 361948,739,304 - 48,771,555 (-)NCBINCBI36Build 36hg18NCBI36
Build 341948,739,303 - 48,771,555NCBI
Celera1940,850,091 - 40,882,209 (-)NCBICelera
Cytogenetic Map19q13.31NCBI
HuRef1940,478,136 - 40,510,489 (-)NCBIHuRef
CHM1_11944,049,115 - 44,081,452 (-)NCBICHM1_1
T2T-CHM13v2.01946,364,840 - 46,397,157 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39724,246,124 - 24,272,863 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl724,245,714 - 24,272,865 (+)EnsemblGRCm39 Ensembl
GRCm38724,546,699 - 24,573,438 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl724,546,289 - 24,573,440 (+)EnsemblGRCm38mm10GRCm38
MGSCv37725,332,169 - 25,358,457 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36724,255,049 - 24,282,192 (+)NCBIMGSCv36mm8
Celera719,161,255 - 19,187,540 (+)NCBICelera
Cytogenetic Map7A3NCBI
cM Map711.42NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049555551,293,416 - 1,315,839 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049555551,293,416 - 1,315,839 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan11951,570,527 - 51,608,367 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01940,485,052 - 40,522,188 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11949,093,928 - 49,125,723 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1949,094,014 - 49,125,520 (-)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11111,548,719 - 111,571,816 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1111,548,719 - 111,571,816 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1111,028,445 - 111,051,541 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01112,158,850 - 112,181,954 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1112,158,850 - 112,181,954 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11111,746,938 - 111,770,215 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01111,380,774 - 111,403,889 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01112,265,054 - 112,288,168 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440934916,407,084 - 16,436,413 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936706751,108 - 783,777 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_004936706752,571 - 783,746 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl650,403,689 - 50,425,729 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1650,403,691 - 50,425,730 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2646,158,742 - 46,180,744 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.1637,062,149 - 37,095,138 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl637,060,439 - 37,095,094 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366607316,603,474 - 16,637,686 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046249071,087,611 - 1,113,266 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046249071,087,611 - 1,113,275 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Xrcc1
121 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:49
Count of miRNA genes:47
Interacting mature miRNAs:47
Prediction methods:Microtar, Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1554320Bmd1Bone mineral density QTL 112.20.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)150910886060548Rat
631688Hcas2Hepatocarcinoma susceptibility QTL 230.0001liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)15925874115540829Rat
2313062Bmd73Bone mineral density QTL 733.90.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)11148131282174945Rat
2313065Bss67Bone structure and strength QTL 673.10.0001tibia area (VT:1000281)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313069Bss68Bone structure and strength QTL 682.90.0001tibia size trait (VT:0100001)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313075Bss66Bone structure and strength QTL 663.40.0001tibia length (VT:0004357)tibia length (CMO:0000450)11148131282174945Rat
2313077Bss69Bone structure and strength QTL 693.50.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)11148131282174945Rat
2313092Bmd72Bone mineral density QTL 722.50.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)11148131282174945Rat
2313097Bss70Bone structure and strength QTL 703.50.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
631495Bp96Blood pressure QTL 964.52arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)122340647102268831Rat
1358359Sradr1Stress Responsive Adrenal Weight QTL 14.74adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)130882023123479925Rat
70225Bp58Blood pressure QTL 583.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132356093162846471Rat
1300172Bp172Blood pressure QTL 1723.56arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)13273727390665040Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132737458199368955Rat
2313051Bss57Bone structure and strength QTL 573.70.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)143284731118944897Rat
2313059Bss55Bone structure and strength QTL 553.20.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313072Bss53Bone structure and strength QTL 534.30.0001tibia length (VT:0004357)tibia length (CMO:0000450)143284731118944897Rat
2313078Bss54Bone structure and strength QTL 543.50.0001tibia area (VT:1000281)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313094Bss58Bone structure and strength QTL 583.70.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)143284731118944897Rat
2313098Bmd70Bone mineral density QTL 703.60.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)143284731118944897Rat
2313099Bss56Bone structure and strength QTL 562.40.0001tibia size trait (VT:0100001)tibia midshaft endosteal cross-sectional area (CMO:0001716)143284731118944897Rat
2302059Pia36Pristane induced arthritis QTL 363.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)14333300288333002Rat
2313402Anxrr24Anxiety related response QTL 24aggression-related behavior trait (VT:0015014)tameness/aggressiveness composite score (CMO:0002136)148963584144267916Rat
4889962Bss94Bone structure and strength QTL 943.8tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)14936146582174945Rat
1578649Bmd8Bone mineral density QTL 84.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)14939317294393172Rat
1578654Bss10Bone structure and strength QTL 104femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)149393172159356837Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)149393289199050459Rat
6903308Scl36Serum cholesterol QTL 3620.0125blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)15386304190532583Rat
4889919Bss86Bone structure and strength QTL 864.1tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)15389511782174945Rat
4889929Bss87Bone structure and strength QTL 876.7tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)15389511782174945Rat
61342Bp27Blood pressure QTL 273.40.0006arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)15673266898773277Rat
2300164Bmd44Bone mineral density QTL 445.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)156949932101949932Rat
2298545Neuinf8Neuroinflammation QTL 84.6nervous system integrity trait (VT:0010566)spinal cord beta-2 microglobulin mRNA level (CMO:0002125)157336763151090257Rat
1300121Hrtrt1Heart rate QTL 13.7heart pumping trait (VT:2000009)heart rate (CMO:0000002)165789093115540829Rat
7421628Bp361Blood pressure QTL 3610.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)166023617118608521Rat
631512Scl6Serum cholesterol level QTL 69.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)17219768090508767Rat
1358192Ept13Estrogen-induced pituitary tumorigenesis QTL 133.4pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)177494165122494165Rat
10054135Gmadr2Adrenal mass QTL 21.970.0129adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)177857876122857876Rat
1549903Bp267Blood pressure QTL 267arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)177876254106047988Rat
61344Bp29Blood pressure QTL 297.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)178350581123350581Rat
7411712Strs4Sensitivity to stroke QTL 48.7cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)178430536123430536Rat
61433Cia2Collagen induced arthritis QTL 25joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)17843075491209302Rat
1582234Gluco18Glucose level QTL 183.40.0003blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)178479925123479925Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2180,168,335 - 80,168,582 (+)MAPPERmRatBN7.2
Rnor_6.0181,441,311 - 81,441,557NCBIRnor6.0
Rnor_5.0182,700,713 - 82,700,959UniSTSRnor5.0
RGSC_v3.4179,859,931 - 79,860,177UniSTSRGSC3.4
Celera174,621,154 - 74,621,400UniSTS
Cytogenetic Map1q21UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 37 49 33 19 33 8 11 74 35 41 11 8
Low 6 8 8 8
Below cutoff


RefSeq Acc Id: ENSRNOT00000027057   ⟹   ENSRNOP00000027057
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl180,141,207 - 80,168,701 (+)Ensembl
Rnor_6.0 Ensembl181,413,353 - 81,441,678 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000096411   ⟹   ENSRNOP00000094456
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl180,141,207 - 80,159,863 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000100887   ⟹   ENSRNOP00000092376
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl180,141,227 - 80,168,683 (+)Ensembl
RefSeq Acc Id: NM_053435   ⟹   NP_445887
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,141,273 - 80,168,705 (+)NCBI
Rnor_6.0181,413,353 - 81,441,680 (+)NCBI
Rnor_5.0182,673,571 - 82,701,082 (+)NCBI
RGSC_v3.4179,834,167 - 79,860,300 (+)RGD
Celera174,594,313 - 74,621,523 (+)RGD
RefSeq Acc Id: XM_017589796   ⟹   XP_017445285
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,141,171 - 80,168,704 (+)NCBI
Rnor_6.0181,413,237 - 81,441,676 (+)NCBI
RefSeq Acc Id: XM_017589797   ⟹   XP_017445286
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,141,169 - 80,168,704 (+)NCBI
Rnor_6.0181,413,236 - 81,441,676 (+)NCBI
RefSeq Acc Id: XM_039092830   ⟹   XP_038948758
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,152,951 - 80,168,704 (+)NCBI
RefSeq Acc Id: XM_039092839   ⟹   XP_038948767
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,152,940 - 80,168,704 (+)NCBI
RefSeq Acc Id: XM_039092840   ⟹   XP_038948768
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,152,936 - 80,168,704 (+)NCBI
RefSeq Acc Id: XM_039092851   ⟹   XP_038948779
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,140,495 - 80,168,704 (+)NCBI
RefSeq Acc Id: XM_039092853   ⟹   XP_038948781
Rat AssemblyChrPosition (strand)Source
mRatBN7.2180,141,445 - 80,168,704 (+)NCBI
RefSeq Acc Id: NP_445887   ⟸   NM_053435
- UniProtKB: Q9ESZ0 (UniProtKB/Swiss-Prot),   Q6IRJ9 (UniProtKB/Swiss-Prot),   A6J8Z7 (UniProtKB/TrEMBL),   A0A8I6AHG8 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_017445286   ⟸   XM_017589797
- Peptide Label: isoform X5
- UniProtKB: A0A8I6AHG8 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_017445285   ⟸   XM_017589796
- Peptide Label: isoform X4
- UniProtKB: A0A8I6AHG8 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000027057   ⟸   ENSRNOT00000027057
RefSeq Acc Id: XP_038948779   ⟸   XM_039092851
- Peptide Label: isoform X6
- UniProtKB: A0A8I6AHG8 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038948781   ⟸   XM_039092853
- Peptide Label: isoform X6
- UniProtKB: A0A8I6AHG8 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038948768   ⟸   XM_039092840
- Peptide Label: isoform X3
- UniProtKB: A0A8I6AHG8 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038948767   ⟸   XM_039092839
- Peptide Label: isoform X2
- UniProtKB: A0A8I6AHG8 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038948758   ⟸   XM_039092830
- Peptide Label: isoform X1
- UniProtKB: A0A8I6AHG8 (UniProtKB/TrEMBL)
RefSeq Acc Id: ENSRNOP00000092376   ⟸   ENSRNOT00000100887
RefSeq Acc Id: ENSRNOP00000094456   ⟸   ENSRNOT00000096411
Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q9ESZ0-F1-model_v2 AlphaFold Q9ESZ0 1-631 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13689799
Promoter ID:EPDNEW_R323
Type:multiple initiation site
Description:X-ray repair cross complementing 1
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.0181,413,321 - 81,413,381EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:619823 AgrOrtholog
BioCyc Gene G2FUF-60438 BioCyc
Ensembl Genes ENSRNOG00000019915 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000027057 ENTREZGENE
  ENSRNOT00000027057.6 UniProtKB/Swiss-Prot
  ENSRNOT00000096411.1 UniProtKB/TrEMBL
  ENSRNOT00000100887.1 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Galactose-binding domain-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro BRCT_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  BRCT_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  BRCT_XRCC1_rpt1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Galactose-bd-like_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Xrcc1_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:84495 UniProtKB/Swiss-Prot
Pfam BRCT UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  BRCT_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  XRCC1_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Xrcc1 PhenoGen
RatGTEx ENSRNOG00000019915 RatGTEx
SMART BRCT UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF49785 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF52113 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  A6J900_RAT UniProtKB/TrEMBL
  Q9ESZ0 ENTREZGENE, UniProtKB/Swiss-Prot
UniProt Secondary Q6IRJ9 UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2016-06-08 Xrcc1  X-ray repair cross complementing 1  Xrcc1  X-ray repair complementing defective repair in Chinese hamster cells 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2004-09-10 Xrcc1  X-ray repair complementing defective repair in Chinese hamster cells 1    x-ray repair cross-complementing group 1 protein  Name updated 1299863 APPROVED
2002-08-07 Xrcc1  x-ray repair cross-complementing group 1 protein      Symbol and Name status set to provisional 70820 PROVISIONAL